Electromyographic Evaluation of Quadriceps During Eccentric Decline Squat

December 16, 2019 updated by: Sevim ACARÖZ CANDAN, T.C. ORDU ÜNİVERSİTESİ

Electromyographic Evaluation of Quadriceps During Eccentric Decline Squat: An Investigation of the Effect of Decline Angle and Arc of Motion

Previous studies have generally investigated patellar tendon stiffness, cross-sectional area of patellar tendon, patellar tendon length, patellar force and patellafemoral forces during decline squat. However, there is just a few study about electromyographic (EMG) activity during the eccentric squating, which is about rectus femoris (RF) recruitment. In the present study the investigators primarly aimed to quantify the activation of RF, vastus lateralis (VL), and vastus medialis obliqus (VMO) during eccentric squat on different decline angle (0, 5°, 10°, 15°, 20°). An additional purpose of our study was to compare the changes in muscle activation at various arc of knee flexion motion (degrees of 0-30, 30-60, 60-90, 0-60, 30-90, 0-90).The investigators hypothesised that the recruitment of RF, VL, and VMO during eccentric squat would differ according to decline angle and arc of motion.

Study Overview

Status

Unknown

Detailed Description

The squat procedure in each condition will be repeated 10 times on a treadmill. The treadmill will be used to adjust the degree of decline in a standard manner. There will be a metronome to keep the speed of exercise in the same rhythm. All squats will be performed with a weighted barbell. The weight of it will be set as in ratio 30% of the participant's body weight

Study Type

Observational

Enrollment (Anticipated)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Altinordu
      • Ordu, Altinordu, Turkey, 52100
        • Sevim ACARÖZ CANDAN

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Asymptomathic older than 18 years, voluntary subjects who are students in a high school of physical education and sports.

Description

Inclusion Criteria:

  • had exercised regularly (>3 days in a week) for at least six months.
  • older than 18 years old.

Exclusion Criteria:

  • had patellofemoral pain, knee pain otherwise unrelated to the knee extensor mechanism and other injuries that would restrict performance of the tasks (e.g. ankle pathology).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Crossover
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Electromyographic measurement of muscle activation
Time Frame: 50 minutes

Surface electromyographic (EMG) system (Noraxon Telemyo DTS System, Scottsdale, USA) will be use to measure the muscle activation ratios of RF, VL, and VMO. Electrodes will be placed according to Surface EMG for noninvasive assessment of muscles (SENIAM) recommendations on the dominant leg.

The muscle activation during eccentric phase of the decline squat for RF, VL, and VMO will be determined. The decline squat will be performed under different conditions (various decline angle: 0, 5, 10,15, 20 degree) The muscle activation will also be investigated within various arc of motion of knee flexion (0-30, 30-60, 60-90, 0-60, 0-90, 30-90) which is determined using the motion analysis system (Noraxon, MYOmotion Scottsdale, USA).

50 minutes
Maximal voluntary isometric contractions (MVICs)
Time Frame: 5 minutes
MVICs for the RF, VL, and VMO at their manual muscle test positions will be assessed within 3 trials, which lasts 5 seconds. The muscle test position will be standardized 90 degrees hip flexion and 60 degrees knee flexion. One minute a rest period will be between each trial. The peak EMG amplitude will be used for the normalization.
5 minutes
Normalized EMG values
Time Frame: 5 minutes
The amount of muscle activation in each condition will be proportioned to MVICs value for normalization using a calculator. The value will be represented in percentile (%).
5 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weight
Time Frame: 1 minute
The participant's weight will be determined a weighing machine inkilogram.
1 minute
Height
Time Frame: 1 minute
The participant's height will be measured in cm.
1 minute

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sevim ACARÖZ CANDAN, PhD, T.C. ORDU ÜNİVERSİTESİ

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

December 15, 2019

Primary Completion (Anticipated)

December 21, 2019

Study Completion (Anticipated)

December 22, 2019

Study Registration Dates

First Submitted

December 6, 2019

First Submitted That Met QC Criteria

December 16, 2019

First Posted (Actual)

December 19, 2019

Study Record Updates

Last Update Posted (Actual)

December 19, 2019

Last Update Submitted That Met QC Criteria

December 16, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Patellar Tendinopathy

3
Subscribe